Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Curium completes acquisition of Monrol

Positions Curium as leading manufacturer of Lu-177 isotope

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506

GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative

The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies

Merck and Zebra Technologies collaborate to create safety and traceability solutions

Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems

Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital

The freshly infused capital will primarily be deployed towards expansion and research & development

Cadila launches Cadilose for constipation and hepatic encephalopathy

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%